Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 trial. Aim. To evaluate the efficacy and safety of two...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | RU |
| Publié: |
State Scientific Center of Dermatovenereology and Cosmetology
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/e87e2e9dcfab4ce2ac14f940344d122b |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|